Mkts

Xilio Therapeutics, Inc.

NASDAQ: XLO
$7.56+0.05 (+0.67%)
As of Nov 20, 4:00 PM ET

Key statistics

Day range
7.077.60
52-week range
6.4711.30
Today
Open7.43
Previous close7.56
Volume2.7K
Valuation
Market cap52.70M
P/E ratio—
EPS (TTM)-1.54
Income & risk
Dividend / yield—
Beta-0.10
Avg volume15.0K
Discussion

XLO News

Stories mentioning XLO from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue12,64813,68619,0668,0842,9302,2632,357
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development19,83218,12214,32115,3308,2668,83610,75911,216
Sales General & Admin
Total Operating Expenses26,76025,52220,99522,45016,78115,35317,02517,061
Operating Income (Loss)(14,112)(11,836)(1,929)(14,366)(13,851)(13,629)(14,762)(14,704)
Interest Income
Interest Expense
Other Expense1,283921.001,022(1,428)586.00536.00742.00779.00
Pretax Income
Tax Provision
Net Income (Loss)(9,529)10,360(16,287)(15,844)(13,265)(13,093)(14,020)(13,925)
Earnings Per Share (Basic)(0.58)1.24(0.11)(0.16)(2.49)(3.43)(0.22)(0.24)
Earnings Per Share (Diluted)(0.58)(1.43)(0.11)(0.16)(2.49)(14.16)(0.22)(0.24)
Weighted Average Shares Outstanding (Basic)16,3488,359144,10796,4485,3363,82263,46557,760
Weighted Average Shares Outstanding (Diluted)

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About XLO

Xilio Therapeutics, Inc. (NASDAQ: XLO) is a stock listed on the Nasdaq Stock Market under the ticker symbol XLO. It last traded at $7.56 (Nov 20, 2026, 4:00 PM ET), up 0.7% on the day. That gives Xilio Therapeutics a market capitalisation of $52.7M.

Over the past 52 weeks XLO has traded between $6.47 and $11.30.

Revenue for the quarter ended Mar 31, 2026 was $12.6M; a net loss of $9.5M. Revenue was up 332% from $2.9M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$12.6M-$9.5M-75.3%
Dec 31, 2025$13.7M$10.4M75.7%
Sep 30, 2025$19.1M-$16.3M-85.4%
Jun 30, 2025$8.1M-$15.8M-196.0%

From Xilio Therapeutics’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…